Respira Therapeutics
Biotechnology, 5901 Indian School Rd Ne, Palo Alto, California, 87110, United States, 1-10 Employees
Who is RESPIRA THERAPEUTICS
Respira Therapeutics is developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of the lung. Respir...
Read More
-
Headquarters: 5901 Indian School Rd Ne, Palo Alto, California, 87110, United States
-
Date Founded: 2010
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8011
Does something look wrong? Fix it. | View contact records from RESPIRA THERAPEUTICS
Respira Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Respira Therapeutics
Answer: Respira Therapeutics's headquarters are located at 5901 Indian School Rd Ne, Palo Alto, California, 87110, United States
Answer: Respira Therapeutics's official website is https://respiratherapeutics.com
Answer: Respira Therapeutics's revenue is $1 Million to $5 Million
Answer: Respira Therapeutics's SIC: 8011
Answer: Respira Therapeutics has 1-10 employees
Answer: Respira Therapeutics is in Biotechnology
Answer: Respira Therapeutics contact info: Phone number: Website: https://respiratherapeutics.com
Answer: Respira Therapeutics is developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of the lung. Respira combines proprietary dry-powder inhaler device technologies and advanced particle engineering-based inhaled drug formulation approaches to develop novel therapeutics that deliver the drug where it needs to be in the lung and lung periphery, instead of in the oropharyngeal cavity. Respiras lead product candidate, RT234-PAH, has received FDA Orphan Drug Designation for Pulmonary Arterial Hypertension and is in Phase 2 clinical trials as a first-in-class inhaled therapeutic for as-needed use to provide acute relief for the most commonly reported symptoms in PAH patients.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month